CVS Test 5 May 2014

22 Questions | Total Attempts: 32

SettingsSettingsSettings
Please wait...
CVS Test 5 May 2014

Questions and Answers
  • 1. 
    CVS 1 Patient 1’s lipogram showed an LDL of 4,5 mmol/L. What does LDL stand for and what is the target LDL level in a diabetic patient. (2)
  • 2. 
    The presence of which two liver enzymes in a liver function test indicate liver damage?(2)
  • 3. 
    Which laboratory test results confirms that the patient is a Type 2 diabetic and what is the target level for diabetic patients on treatment. (2)
  • 4. 
    What treatments did the patient receive for dyslipidemia and diabetes? (2)
  • 5. 
    CVS 1 Patient 2 is currently receiving treatment for hypertension, diabetes and hypercholesterolaemia. The patients’ total cholesterol is 5,2 mmol/L and his triglycerides are 3,1 mmol/L. Is this patient at goal. If not, what is the goal? (3)
  • 6. 
    If the patients triglycerides are not at goal at the 3 month follow up consultation what add-on therapy can be considered as an add-on to atorvastatin? (1)
  • 7. 
    CVS 2 Patient 1 treatment was changed from  furosemide and atenolol to indapamide SR and Carvedilol 25 mg once daily. Why was his treatment changed? (1)
  • 8. 
     What is PSA and why do men get a PSA test? (3)
  • 9. 
    Give 3 common symptoms associated with adult-onset testosterone deficiency? (3)
  • 10. 
    What treatment is suggested for erectile dysfunction? (1)
  • 11. 
    Define PHARMACOVIGILANCE? (2)
  • 12. 
    Side effects are wanted but natural and anticipated consequences of medical treatment.”
    • A. 

      True

    • B. 

      False

  • 13. 
    Adverse Drug reactions are unwanted and unintended consequence of medical treatment” This may include lack of efficacy and events relating to abuse or overdose.
    • A. 

      True

    • B. 

      False

  • 14. 
    Adverse events are adverse effects that may or may not be caused by the suspect drug
    • A. 

      True

    • B. 

      False

  • 15. 
    What does NADEMC stands for?
  • 16. 
    Why do we need to report adverse events?
  • 17. 
    Bioequivalence: The absence of a significant difference in bioavailability between two pharmaceutically equivalent products, or two pharmaceutically alternative products, under similar conditions in an appropriately designed study. (Refers to the equivalence in the release of the API from the two products).
    • A. 

      True

    • B. 

      False

  • 18. 
    Define Bioavailability:
  • 19. 
    Two treatments are not different from one another if the 90% confidence interval of the ratio of a log-transformed exposure measure (AUC and/or Cmax) falls completely within the range 80-125%.
    • A. 

      True

    • B. 

      False

  • 20. 
    Define Tmax? (2)
  • 21. 
    Define Cmax? (2)
  • 22. 
    Innovator companies file a patent for 20 years 
    • A. 

      True

    • B. 

      False

Back to Top Back to top